March 17, 2015
The use of robot-assisted surgery and modern radiation techniques have been rapidly adopted as treatments for prostate cancer, but a UNC Lineberger Comprehensive Cancer Center researcher is asking what the newer technologies will mean in terms of side effects and outcomes for patients in the long-term.
March 11, 2015
Lowry Caudill, PhD is the chair of the UNC Board of Trustees. He is also a prostate cancer survivor. On January 24, 2015, Caudill told his story before 300 UNC Lineberger supporters at the 28th Annual Lineberger Club Lunch and Basketball Game.
February 16, 2015
Robert Johnson always has an annual physical exam and attends the prostate cancer screening offered at his local hospital. “African-American men are more susceptible to prostate cancer, so if I have a problem, I want to catch it early.”
January 28, 2015
A UNC Lineberger researcher has pointed to a need for more data on whether new technology designed to better detect men at higher-risk for prostate cancer will also mean improvements in survival rates and symptoms.
September 8, 2014
New clinical guidelines have been announced for the treatment of men with metastatic castration-resistant prostate cancer (CRPC) by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). Ethan Basch, MD, director of the Cancer Outcomes Research Program at UNC Lineberger Comprehensive Cancer Center, served as the co-chair of the ASCO/CCO expert panel that developed the guideline.
April 25, 2014
UNC Lineberger has been selected to participate in A Survivor Action Partnership – United States of America (ASAP USA), a consortium of institutions that will collaborate to develop and study interventions to improve the lives of prostate cancer survivors in the United States. Sixteen institutions were selected following a peer reviewed application process. Ronald Chen, MD, MPH, assistant professor of radiation oncology is leading the UNC Lineberger ASAP USA team.
November 11, 2013
Stereotactic body radiation therapy is an effective treatment option that is cost-effective and convenient for patients.
October 28, 2013
Five questions for Ronald Chen, a James Woods Young Faculty Award recipient dedicated to bettering treatment for cancer patients.
October 24, 2013
Only half of the men who receive a prostate cancer diagnosis consult with more than one type of physician before deciding on a course of treatment.
September 25, 2013
Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.
